Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment
Author:
Affiliation:
1. Formerly of Novexel SA; Romainville France
2. AstraZeneca; Macclesfield UK
3. AstraZeneca; Waltham MA USA
Funder
Novexel
AstraZeneca
Allergan plc
Publisher
Wiley
Subject
Pharmacology (medical),Pharmacology
Reference24 articles.
1. Current concepts in antimicrobial therapy against resistant Gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa;Kanj;Mayo Clin Proc,2011
2. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases;Munoz-Price;Lancet Infect Dis,2013
3. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae;Aktas;Int J Antimicrob Agents,2012
4. Kinetics of avibactam inhibition against Class A, C, and D beta-lactamases;Ehmann;J Biol Chem,2013
5. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases;Lagace-Wiens;Antimicrob Agents Chemother,2011
Cited by 42 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dosing Evaluation of Ceftazidime–Avibactam in Intensive Care Unit Patients Based on Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling and Simulation;Antibiotics;2024-09-09
2. Clinical Outcomes of Ceftazidime–Avibactam versus Ceftolozane–Tazobactam in Managing Pseudomonal Infections in Patients Undergoing Renal Replacement Therapy;Antibiotics;2024-07-26
3. Adequacy of the Dosing and Infusion Time of Ceftazidime/Avibactam for the Treatment of Gram-Negative Bacterial Infections: A PK/PD Simulation Study;Infection and Drug Resistance;2024-07
4. Safety evaluation of ceftazidime/avibactam based on FAERS database;Infection;2024-06-06
5. Exploring the World of ß-Lactamase Inhibitors;Advances in Medical Technologies and Clinical Practice;2024-04-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3